MedTrace Logo

Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI

NCT03404648 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2021-02-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out if a PET/MR scan in combination with standard MRI and CT scans can improve the early detection and treatment of patients with prostate cancer.

Conditions

  • Prostate Adenocarcinoma

Interventions

DRUG

C-11 choline PET tracer

C-11 choline PET tracer, One dose, totally 12-14 millicurie (mCi), intravenous administration while patient is lying on the table.

DRUG

Gadobutrol

Single dose of Gadavist® (Gadobutrol, Bayer) at no more than 0.1 mmol/kg will be administrated intravenously.

DEVICE

PET/MR scanner

C11-PET/MR and pelvic mpMRI scan for prostate cancer.

Sponsors & Collaborators

Principal Investigators

  • Ming Yang · Mayo Clinic

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2020-01-23
Completion
2020-01-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03404648 on ClinicalTrials.gov